Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics, Inc. - Common Stock (NQ:SRNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sorrento Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Market Briefing For Monday, Aug. 23
We might be near a moment of truth for the Senior Indexes, either in just a few days or postponed until after Labor Day. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares... 
Via Benzinga
Market Briefing For Tuesday, Aug. 17
Momentum grows for a Fed taper. Investor risk now is no more than just a couple weeks ago. Actually a Fed movement is a plus as it suggest they're a believe in economic growth; which will be favorable... 
Via Talk Markets
Topics Economy
Why Sorrento Therapeutics' Stock Is Trading Higher Today
Sorrento Therapeutics (NASDAQ:SRNE) shares are trading hig... 
Via Benzinga
Market Briefing For Wednesday, July 21
Via Talk Markets
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Market Briefing For Monday, Aug. 16
Too many permabears are almost delirious with negativity and still give extremely bearish outlooks, when that's not a correct read of markets. 
Via Talk Markets
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
Why Dynavax, Novavax, and Sorrento Soared This Week
There were different reasons behind each of these COVID-19 vaccine stocks' big gains. 
Via The Motley Fool
Market Briefing For Thursday, Aug. 12
Fear and hysteria are not engineered by Washington about COVID, however it is a 'mood' to factor into everything from media to stock market projections. 
Via Talk Markets
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to... 
Via Benzinga
Market Briefing For Tuesday, Aug. 10
Most markets held gains as the total backdrop has not changed. Lots of money managers are eager to see a decline, to put more money 'in', but the market hasn't cooperated by dropping 'much'. 
Via Talk Markets
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Thinking About Buying Stock In AMD, General Motors Or Sorrento Therapeutics?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Market Briefing For Monday, Aug. 9
Ultimately energy markets will envision post-pandemic era robust economic activity resuming, even though Covid surges temporarily squelch demand. 
Via Talk Markets
Cramer Advises Viewers On Palantir, SoFi And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand why is MKS Instruments, Inc. (NASDAQ: MKSI) trading so cheap. He would be a buyer.... 
Via Benzinga
Market Briefing For Wednesday, Aug. 4
'Subject to mandate' seems to be a catch-phrase these days; mandates to fly, to eat, to drink in a pub, to go to a show, and even to govern New York (of course that last one was an effort at humor,... 
Via Talk Markets
Market Briefing For Tuesday, Aug. 3
We do see Tuesday turnaround as a rebound from Monday's just modest fade. Again our wildcard continues to be Covid; and the 'presumed' dovish Fed as relates to 'tapering'. 
Via Talk Markets
Topics Economy
Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen... 
Via Benzinga
Market Briefing For Monday, Aug. 2
We're 'not' in a global financial crisis; but we are failing the 'synchronized global recovery', due to the worldwide pandemic. 
Via Talk Markets
Market Briefing For Thursday, July 29
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines. 
Via Talk Markets
Market Briefing For Wednesday, July 28
Tolls being taken out of the market for those overstaying not just Chinese stocks, but the S&P and NDX behemoths as well. Solid earnings are 'in the mix' (discounted) of course, and it's the guidance... 
Via Talk Markets
Topics Stocks
Market Briefing For Thursday, July 22
The post-COVID era has not arrived yet, and that cuts to the chase of what's bothering markets and prospects for the economy. The optimistic hope is to keep everything open on a presumed basis, because... 
Via Talk Markets
Topics Economy
Unusual Options Activity Insight: Sorrento Therapeutics
Shares of Sorrento Therapeutics (NASDAQ:SRNE) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $9.16. Sentiment:... 
Via Benzinga
Sorrento Starts Patient Dosing In Mid-Stage COVID-19 Trial With Nasal Neutralizing Antibody
Sorrento Therapeutics Inc (NASDAQ: SRNE) has started dosing COVID-19 patients in its Phase 2 efficacy trial. This study uses a decentralized design where... 
Via Benzinga
Market Briefing For Wednesday, July 14
Negative divergences increasingly creeping into the NY market are reflected a good bit by the S&P shuffles, and overall big-board technicals. Though, yields were up with a mediocre Treasury Auction,... 
Via Talk Markets
Topics Stocks
Unusual Options Activity Insight: Sorrento Therapeutics
On Monday, shares of Sorrento Therapeutics (NASDAQ:SRNE) saw unusual options activity. After the option alert, the stock price moved down to $8.31. Sentiment: BULLISH Option... 
Via Benzinga
Why Sorrento Therapeutics Is Down 9% This Week
Investors apparently weren't impressed by good news about the company's promising RTX. 
Via The Motley Fool
Why Sorrento Therapeutics Stock Gained 29% Last Month
The rally has more to do with the stock's pre-June circumstances than recent news. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.